The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Abstract
Purpose: The treatment of acute myeloid leukemia (AML) in first relapse is associated with unsatisfactory rates of complete responses that usually are short lived. Therefore, a clinically useful prognostic index can facilitate therapeutic decision making and evaluation of investigational treatment strategies at relapse of AML. Patients and Methods: A prognostic score is presented based on the multivariate analysis of 667 AML patients in first relapse among 1,540 newly diagnosed non-M3 AML patients (age 15 to 60 years) entered onto three successive Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research Collaborative Group trials. Results: Four clinically relevant parameters are included in this index (ie, length of relapse-free interval after first complete remission, cytogenetics at diagnosis, age at relapse, and whether previous stem-cell transplantation was performed). Using this stratification system, three risk groups were defined: a favorable prognostic group A (overall survival [OS] of 70% at 1 year and 46% at 5 years), an intermediate-risk group B (OS of 49% at 1 year and 18% at 5 years), and a poor-risk group C (OS of 16% at 1 year and 4% at 5 years). Conclusion: The prognostic index estimates the outcome of AML patients in first relapse using four commonly applied clinical parameters and might identify patients who are candidates for salvage and investigational therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Statistical Inference Under Order Restrictions
Kalbfleisch, J. D. (1975) · Technometrics · doi:10.1080/00401706.1975.10489288 · Cited by 1,546
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Wheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R. F., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 434
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationDöhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Self-citationEstey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Acute myeloid leukaemia in adults
Ferrara, F., & Schiffer, C. A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61727-9 · Cited by 563
An update of current treatments for adult acute myeloid leukemia
Dombret, H., & Gardin, C. (2016) · Blood · doi:10.1182/blood-2015-08-604520 · Cited by 550
Kantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J. M., List, A., Fenaux, P., Sanz, G., Issa, J., et al. (2008) · Cancer · doi:10.1002/cncr.23697 · Cited by 482
Cornelissen, J. J., van Putten, W. L. J., Verdonck, L. F., Theobald, M., Jacky, E., Daenen, S. M. G., van Marwijk Kooy, M., Wijermans, P., Schouten, H., Huijgens, P. C., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025627 · Cited by 471
Self-citationHoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 463
Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000349 · Cited by 458
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Wei, A. H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B., Dombret, H., Ravandi, F., Sayar, H., Jang, J.-H., Porkka, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004444 · Cited by 445
Self-citationYin, J. A. L., O'Brien, M. A., Hills, R. K., Daly, S. B., Wheatley, K., & Burnett, A. K. (2012) · Blood · doi:10.1182/blood-2012-06-435669 · Cited by 425
Cornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhäuser, M., Juliusson, G., Råcil, Z., Rowe, J. M., Russell, N., Mohty, M., et al. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.150 · Cited by 400
Self-citationRavandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-480228 · Cited by 381
Acute myeloid leukemia: 2019 update on risk‐stratification and management
Estey, E. H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25214 · Cited by 371
Perna, F., Berman, S. H., Soni, R. K., Mansilla-Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C. W., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 346
Acute Myeloid Leukemia: A Concise Review
Saultz, J., & Garzon, R. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5030033 · Cited by 342
Klco, J. M., Miller, C. A., Griffith, M., Petti, A., Spencer, D. H., Ketkar-Kulkarni, S., Wartman, L. D., Christopher, M., Lamprecht, T. L., Helton, N. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.9643 · Cited by 339
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 336
Stein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R., Flinn, I. W., et al. (2019) · Blood · doi:10.1182/blood-2018-08-869008 · Cited by 331
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 303
Treatment of Relapsed Acute Myeloid Leukemia
Thol, F., & Ganser, A. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00765-5 · Cited by 288
Heuser, M., Ofran, Y., Boissel, N., Brunet Mauri, S., Craddock, C., Janssen, J., Wierzbowska, A., & Buske, C. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.018 · Cited by 284
Norsworthy, K. J., Ko, C.-W., Lee, J. E., Liu, J., John, C. S., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0604 · Cited by 269
Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230
Reporting methods in studies developing prognostic models in cancer: a review
Mallett, S., Royston, P., Dutton, S., Waters, R., & Altman, D. G. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-20 · Cited by 206
“Patients recruited from RCTs in 11% (5) of the studies [14,38,40,44,47].”
BackgroundMethodInfluentialReporting performance of prognostic models in cancer: a review.
Mallett, S., Royston, P., Waters, R., Dutton, S., & Altman, D. G. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-21 · Cited by 195
Cortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., et al. (2015) · Cancer · doi:10.1002/cncr.28974 · Cited by 175
Milligan, D. W., Wheatley, K., Littlewood, T., Craig, J. I. O., Burnett, A. K., & for the NCRI Haematological Oncology Clinical Studies Group (2006) · Blood · doi:10.1182/blood-2005-10-4202 · Cited by 141
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
Blum, W., Klisovic, R. B., Becker, H., Yang, X., Rozewski, D. M., Phelps, M. A., Garzon, R., Walker, A., Chandler, J. C., Whitman, S. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3339 · Cited by 87
Ravandi, F., Gojo, I., Patnaik, M. M., Minden, M. D., Kantarjian, H., Johnson-Levonas, A. O., Fancourt, C., Lam, R., Jones, M. B., Knox, C. D., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.004 · Cited by 57
Guo, D., Zhao, Y., Wang, N., You, N., Zhu, W., Zhang, P., Ren, Q., Yin, J., Cheng, T., & Ma, X. (2021) · Blood · doi:10.1182/blood.2020008229 · Cited by 36
DeAngelo, D. J., Brunner, A. M., Werner, L., Avigan, D., Fathi, A. T., Sperling, A. S., Washington, A., Stroopinsky, D., Rosenblatt, J., McMasters, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.24968 · Cited by 16
Metadata
- Authors
- Breems, D. A., Van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., De Greef, G. E., Jacky, E., Van der Lelie, J., Boogaerts, M. A., & Löwenberg, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-03-20
- Volume
- 23
- Issue
- 9
- Pages
- 1969-1978
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097192169
- Cited by
- 511
- References
- 17
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.